{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:37:08Z","timestamp":1792787828249,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Natural Science Foundation of China","award":["32400789 and 82504808"],"award-info":[{"award-number":["32400789 and 82504808"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-026-05032-y","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:23:57Z","timestamp":1785198237000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Belumosudil-associated neurological adverse events: evidence from FAERS and experimental validation"],"prefix":"10.1186","volume":"26","author":[{"given":"Zeng-hui","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-jing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"5032_CR1","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41392-022-01147-z","volume":"7","author":"H Gong","year":"2022","unstructured":"Gong H, et al. Dendritic cell-derived IL-27 p28 regulates T cell program in pathogenicity and alleviates acute graft-versus-host disease. Signal Transduct Target Ther. 2022;7:319.","journal-title":"Signal Transduct Target Ther"},{"key":"5032_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2016-06-686618","volume":"129","author":"KP MacDonald","year":"2017","unstructured":"MacDonald KP, Hill GR, Blazar BR. Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood. 2017;129:13\u201321.","journal-title":"Blood"},{"key":"5032_CR3","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1056\/NEJMra1703472","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med. 2017;377:2565\u201379.","journal-title":"N Engl J Med"},{"key":"5032_CR4","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1016\/j.bbmt.2016.06.020","volume":"22","author":"M Grube","year":"2016","unstructured":"Grube M, et al. Risk factors and outcome of chronic graft-versus-host disease after allogeneic stem cell transplantation-results from a single-center observational study. Biol Blood Marrow Transpl. 2016;22:1781\u201391.","journal-title":"Biol Blood Marrow Transpl"},{"key":"5032_CR5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.blre.2018.11.001","volume":"34","author":"EA Copelan","year":"2019","unstructured":"Copelan EA, Chojecki A, Lazarus HM, Avalos BR. Allogeneic hematopoietic cell transplantation; the current renaissance. Blood Rev. 2019;34:34\u201344.","journal-title":"Blood Rev"},{"key":"5032_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2022.12.024","volume":"90","author":"E Baumrin","year":"2024","unstructured":"Baumrin E, Loren AW, Falk SJ, Mays JW, Cowen EW. Chronic graft-versus-host disease. Part I: Epidemiology, pathogenesis, and clinical manifestations. J Am Acad Dermatol. 2024;90:1\u201316.","journal-title":"J Am Acad Dermatol"},{"key":"5032_CR7","doi-asserted-by":"crossref","unstructured":"Carpenter PA et al. A phase II\/III randomized, multicenter trial of prednisone\/sirolimus versus prednisone\/ sirolimus\/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801. Haematologica. 2018;103:1915\u20131924.","DOI":"10.3324\/haematol.2018.195123"},{"key":"5032_CR8","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1182\/blood-2014-08-551994","volume":"125","author":"ME Flowers","year":"2015","unstructured":"Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood. 2015;125:606\u201315.","journal-title":"Blood"},{"key":"5032_CR9","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41409-020-01122-8","volume":"56","author":"K Maas-Bauer","year":"2021","unstructured":"Maas-Bauer K, et al. Ruxolitinib-ECP combination treatment for refractory severe chronic graft-versus-host disease. Bone Marrow Transpl. 2021;56:909\u201316.","journal-title":"Bone Marrow Transpl"},{"key":"5032_CR10","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","volume":"130","author":"D Miklos","year":"2017","unstructured":"Miklos D, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017;130:2243\u201350.","journal-title":"Blood"},{"key":"5032_CR11","doi-asserted-by":"crossref","unstructured":"Doki N et al. An open-label, single-arm, multicenter study of Ibrutinib in Japanese patients with steroid-dependent\/refractory chronic graft-versus-host disease. Transplant Cell Ther. 2021;27:e861\u2013867 e869.","DOI":"10.1016\/j.jtct.2021.05.019"},{"key":"5032_CR12","doi-asserted-by":"crossref","unstructured":"Wang D et al. Efficiency and toxicity of ruxolitinib as a salvage treatment for steroid-refractory chronic graft-versus-host disease. Front Immunol. 2021;12:673636.","DOI":"10.3389\/fimmu.2021.673636"},{"key":"5032_CR13","first-page":"1677","volume":"81","author":"HA Blair","year":"2021","unstructured":"Blair HA. Belumosudil: first approval drugs. 2021;81:1677\u201382.","journal-title":"Belumosudil: first approval drugs"},{"key":"5032_CR14","doi-asserted-by":"crossref","unstructured":"Chin MM et al. Belumosudil combination therapy for chronic graft-versus-host-disease in real-world clinical practice. Bone Marrow Transpl. 2024;60:393\u20135.","DOI":"10.1038\/s41409-024-02476-z"},{"key":"5032_CR15","doi-asserted-by":"publisher","first-page":"16814","DOI":"10.1073\/pnas.1414189111","volume":"111","author":"A Zanin-Zhorov","year":"2014","unstructured":"Zanin-Zhorov A, et al. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci U S A. 2014;111:16814\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5032_CR16","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1182\/blood-2015-10-678706","volume":"127","author":"R Flynn","year":"2016","unstructured":"Flynn R, et al. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood. 2016;127:2144\u201354.","journal-title":"Blood"},{"key":"5032_CR17","doi-asserted-by":"publisher","first-page":"108823","DOI":"10.1016\/j.clim.2021.108823","volume":"230","author":"A Zanin-Zhorov","year":"2021","unstructured":"Zanin-Zhorov A, Blazar BR. ROCK2, a critical regulator of immune modulation and fibrosis has emerged as a therapeutic target in chronic graft-versus-host disease. Clin Immunol. 2021;230:108823.","journal-title":"Clin Immunol"},{"key":"5032_CR18","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12916-024-03348-5","volume":"22","author":"Y Wang","year":"2024","unstructured":"Wang Y, et al. A phase II study of belumosudil for chronic graft-versus-host disease in patients who failed at least one line of systemic therapy in China. BMC Med. 2024;22:142.","journal-title":"BMC Med"},{"key":"5032_CR19","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1002\/ajh.27424","volume":"99","author":"Y Inamoto","year":"2024","unstructured":"Inamoto Y, et al. An open-label study of belumosudil, a selective ROCK2 inhibitor, as second or subsequent line of therapy for steroid-dependent\/steroid-resistant chronic GVHD. Am J Hematol. 2024;99:1917\u201326.","journal-title":"Am J Hematol"},{"key":"5032_CR20","doi-asserted-by":"publisher","first-page":"1339721","DOI":"10.3389\/fphar.2024.1339721","volume":"15","author":"Y He","year":"2024","unstructured":"He Y, Zhang R, Shen H, Liu Y. A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for denosumab. Front Pharmacol. 2024;15:1339721.","journal-title":"Front Pharmacol"},{"key":"5032_CR21","doi-asserted-by":"crossref","unstructured":"Wu J et al. Post-marketing safety evaluation of Vortioxetine: a decade-long pharmacovigilance study based on the FAERS database. J Affect Disord. 202515:379:586\u201393.","DOI":"10.1016\/j.jad.2025.03.007"},{"key":"5032_CR22","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1038\/s41598-018-20755-w","volume":"8","author":"EJ Jin","year":"2018","unstructured":"Jin EJ, et al. Akt regulates neurite growth by phosphorylation-dependent inhibition of radixin proteasomal degradation. Sci Rep. 2018;8:2557.","journal-title":"Sci Rep"},{"key":"5032_CR23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s00018-025-05660-6","volume":"82","author":"Y Hu","year":"2025","unstructured":"Hu Y, et al. Loss of NgBR causes neuronal damage through decreasing KAT7-mediated RFX1 acetylation and FGF1 expression. Cell Mol Life Sci. 2025;82:140.","journal-title":"Cell Mol Life Sci"},{"key":"5032_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12964-020-00588-9","volume":"18","author":"Y Wu","year":"2020","unstructured":"Wu Y, et al. Exogenous fibroblast growth factor 1 ameliorates diabetes-induced cognitive decline via coordinately regulating PI3K\/AKT signaling and PERK signaling. Cell Commun Signal. 2020;18:81.","journal-title":"Cell Commun Signal"},{"key":"5032_CR25","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1182\/blood.2021012021","volume":"138","author":"C Cutler","year":"2021","unstructured":"Cutler C, et al. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood. 2021;138:2278\u201389.","journal-title":"Blood"},{"key":"5032_CR26","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1158\/1078-0432.CCR-21-4176","volume":"28","author":"D Przepiorka","year":"2022","unstructured":"Przepiorka D, et al. Approval summary: belumosudil for adult and pediatric patients 12 years and older with chronic GvHD after two or more prior lines of systemic therapy. Clin Cancer Res. 2022;28:2488\u201392.","journal-title":"Clin Cancer Res"},{"key":"5032_CR27","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1200\/JCO.20.02754","volume":"39","author":"M Jagasia","year":"2021","unstructured":"Jagasia M, et al. ROCK2 Inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease. J Clin Oncol. 2021;39:1888\u201398.","journal-title":"J Clin Oncol"},{"key":"5032_CR28","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/ceo.14347","volume":"52","author":"NB Kantor","year":"2024","unstructured":"Kantor NB, Tovar A, Wang T, Galor A. How does ocular graft-versus-host disease fit under the dry eye umbrella? A review. Clin Exp Ophthalmol. 2024;52:167\u201385.","journal-title":"Clin Exp Ophthalmol"},{"key":"5032_CR29","doi-asserted-by":"crossref","unstructured":"Glotfelty EJ et al. The RhoA-ROCK1\/ROCK2 pathway exacerbates inflammatory signaling in immortalized and primary microglia. Cells. 2023;12:1367.","DOI":"10.3390\/cells12101367"},{"key":"5032_CR30","doi-asserted-by":"publisher","first-page":"8402","DOI":"10.1007\/s12035-024-04108-5","volume":"61","author":"X Fan","year":"2024","unstructured":"Fan X, et al. LPAR6 Participates in Neuropathic Pain by Mediating Astrocyte Cells via ROCK2\/NF-kappaB Signal Pathway. Mol Neurobiol. 2024;61:8402\u201313.","journal-title":"Mol Neurobiol"},{"key":"5032_CR31","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.bbi.2024.01.004","volume":"117","author":"EF Willis","year":"2024","unstructured":"Willis EF, et al. ROCK2 regulates microglia proliferation and neuronal survival after traumatic brain injury. Brain Behav Immun. 2024;117:181\u201394.","journal-title":"Brain Behav Immun"},{"key":"5032_CR32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.expneurol.2009.12.017","volume":"222","author":"K Okada","year":"2010","unstructured":"Okada K, et al. Methylcobalamin increases Erk1\/2 and Akt activities through the methylation cycle and promotes nerve regeneration in a rat sciatic nerve injury model. Exp Neurol. 2010;222:191\u2013203.","journal-title":"Exp Neurol"},{"key":"5032_CR33","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/s41598-024-78933-y","volume":"15","author":"Y Yoshimura","year":"2025","unstructured":"Yoshimura Y, et al. Methylcobalamin-containing nanofiber sheets have better neuroprotective effects than small intestinal submucosa sheets. Sci Rep. 2025;15:950.","journal-title":"Sci Rep"},{"key":"5032_CR34","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1098\/rstb.2006.1894","volume":"361","author":"LF Reichardt","year":"2006","unstructured":"Reichardt LF. Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci. 2006;361:1545\u201364.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"5032_CR35","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1038\/s41380-024-02831-y","volume":"30","author":"SL D\u2019Addario","year":"2025","unstructured":"D\u2019Addario SL, et al. ErbB inhibition rescues nigral dopamine neuron hyperactivity and repetitive behaviors in a mouse model of fragile X syndrome. Mol Psychiatry. 2025;30:2183\u201396.","journal-title":"Mol Psychiatry"},{"key":"5032_CR36","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1002\/glia.23871","volume":"68","author":"DW Lee","year":"2020","unstructured":"Lee DW, et al. Schwann cells selectively myelinate primary motor axons via neuregulin-ErbB signaling. Glia. 2020;68:2585\u2013600.","journal-title":"Glia"},{"key":"5032_CR37","doi-asserted-by":"publisher","first-page":"4506","DOI":"10.1523\/JNEUROSCI.3521-15.2016","volume":"36","author":"E Domenech-Estevez","year":"2016","unstructured":"Domenech-Estevez E, et al. Akt regulates axon wrapping and myelin sheath thickness in the PNS. J Neurosci. 2016;36:4506\u201321.","journal-title":"J Neurosci"},{"key":"5032_CR38","doi-asserted-by":"publisher","first-page":"e11903","DOI":"10.7554\/eLife.11903","volume":"5","author":"X Guo","year":"2016","unstructured":"Guo X, Snider WD, Chen B. GSK3beta regulates AKT-induced central nervous system axon regeneration via an eIF2Bepsilon-dependent, mTORC1-independent pathway. Elife. 2016;5:e11903.","journal-title":"Elife"},{"key":"5032_CR39","doi-asserted-by":"publisher","first-page":"121039","DOI":"10.1016\/j.jad.2025.121039","volume":"398","author":"M Zhang","year":"2025","unstructured":"Zhang M, et al. A real-world pharmacovigilance study of modafinil events in the FDA Adverse Event Reporting System (FAERS). J Affect Disord. 2025;398:121039.","journal-title":"J Affect Disord"},{"key":"5032_CR40","doi-asserted-by":"publisher","unstructured":"Hong X et al. Anticoagulant-associated bleeding: real-world data-driven pharmacovigilance and insights for bleeding management. Int J Surg. 2025. https:\/\/doi.org\/10.1097\/JS9.0000000000004467.","DOI":"10.1097\/JS9.0000000000004467"},{"key":"5032_CR41","doi-asserted-by":"crossref","unstructured":"Murray M, Schifano F, Chiappini S, Corkery JM, Guirguis A. Potential eye disorders in people with and without Type 2 diabetes mellitus exposed to GLP-1 receptor agonists; an examination of the FAERS (FDA Adverse Event reporting System) database. Am J Ophthalmol. 2025283:279\u201390.","DOI":"10.1016\/j.ajo.2025.12.015"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-05032-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05032-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05032-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:02:48Z","timestamp":1792684968000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-05032-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5032"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-05032-y","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"14 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication.","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"665"}}